Erbitux Approved for Metastatic Head and Neck Cancer - MPR
Links shared publicly online about this topic.
- 0total visits
Erbitux Approved for Metastatic Head and Neck Cancer - MPR
empr.com —
View full resource at empr.com
Tags: Cancer, Chemotherapy, Head and Neck Cancer, Erbitux, Bristol-Myers Squibb, Oncology
Most Recently Shared on November 7, 2011 at 8:28 pm By:
Erbitux Gains Expanded Indication for Metastatic Head and Neck Cancer http://t.co/nqnyHzHm #oncology
FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 9, 2011 at 1:05 pm By:
US FDA approval for expanded use of Erbitux | Oral Cancer News
oralcancernews.org — “US FDA approval for expanded use of Erbitux | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 9, 2011 at 8:24 am By:
FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 8, 2011 at 2:00 pm By:
Erbitux (Cetuximab) Approved For Metastatic Head And Neck Cancer, USA
medicalnewstoday.com — “Erbitux (cetuximab) has been approved by the US FDA for combination use with chemotherapy for late-stage head and neck cancer treatment. When given together with chemotherapy, Erbitus was found to” View full resource at medicalnewstoday.com
Most Recently Shared on November 8, 2011 at 7:05 am By:
MNT Drug Approvals Health News
Erbitux (cetuximab) Approved For Metastatic Head And Neck Cancer, USA http://t.co/zZZhKwbc #regulatory
FDA approves Erbitux to treat late-stage head and neck cancer
fda.gov — “The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.” View full resource at fda.gov
Most Recently Shared on November 7, 2011 at 7:27 pm By:
NCI Cancer Bulletin Health News
FDA approves Erbitux, in combination w/ chemotherapy, to treat late-stage head & neck cancer (release) http://t.co/bMtFRAyA
Erbitux recognized as one of the major clinical cancer advances of 2009
news-medical.net — “The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).” View full resource at news-medical.net
Most Recently Shared on November 16, 2009 at 5:23 pm By:
Lung Cancer News: Erbitux recognized as one of the major clinical cancer advances of 2009: The.. http://digg.com/u1GTsp
Advertisement
